Immunovant Inc Total Assets
Immunovant Inc total assets. Based on the latest financial reports, Immunovant Inc (IMVT) holds total assets worth $852.49 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Immunovant Inc (IMVT) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Immunovant Inc (2018–2026)
Total assets of Immunovant Inc from 2018 to 2026. This chart illustrates how Immunovant Inc's total assets have evolved over time, based on quarterly financial data. See latest Immunovant Inc stock price today for real-time trading data and today's change.
Immunovant Inc - Asset Composition Analysis
Immunovant Inc Total Assets Breakdown (March 2026)
Immunovant Inc total assets breakdown as of March 2026. Immunovant Inc's total assets of $852.49 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.2% |
| Accounts Receivable | $3.95 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2026)
This chart illustrates how Immunovant Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Immunovant Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunovant Inc's current assets represent 99.1% of total assets in 2026, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 94.2% of total assets in 2026, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Immunovant Inc Competitors by Total Assets
Key competitors of Immunovant Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Immunovant Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.27 | 12.32 | 19.86 |
| Quick Ratio | 7.27 | 12.32 | 19.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $734.08 Million | $598.86 Million | $535.41 Million |
Immunovant Inc - Advanced Valuation Insights
This section examines the relationship between Immunovant Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.02 |
| Latest Market Cap to Assets Ratio | 6.45 |
| Asset Growth Rate (YoY) | 23.4% |
| Total Assets | $957.57 Million |
| Market Capitalization | $6.18 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Immunovant Inc's assets at a significant premium (6.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Immunovant Inc's assets grew by 23.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunovant Inc (2018–2026)
The table below shows the annual total assets of Immunovant Inc from 2018 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $957.57 Million | +23.36% |
| 2025-03-31 | $776.22 Million | +16.43% |
| 2024-03-31 | $666.71 Million | +64.28% |
| 2023-03-31 | $405.84 Million | -21.28% |
| 2022-03-31 | $515.56 Million | +24.99% |
| 2021-03-31 | $412.49 Million | +277.09% |
| 2020-03-31 | $109.39 Million | +26909.14% |
| 2019-03-31 | $405.00K | +257.87% |
| 2018-03-31 | $113.17K | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more